Literature DB >> 10632738

Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr.

P Molho1, N Rolland, T Lebrun, G Dirat, J P Courpied, T Croughs, I Duprat, Y Sultan.   

Abstract

One hundred and 16 patients contributed to an analysis of the impact of the consequences of severe haemophilia A or B (factor levels < 2%) on orthopaedic status, resources consumed in relation to this status and resultant cost, and quality of life as perceived by the patient, using the MOS 36-Item-Short-Form Health Survey (SF-36). This French cross-sectional study involved outpatients regularly attending a haemophilia treatment centre. Data were collected retrospectively over a period of 1 year by the physician of the haemophilia treatment centre. Patients had a mean age of 23, and consisted of 50% students, 25% salaried workers, 17.2% with no professional activity and 7.8% physically impaired; 82.8% of them had type A haemophilia. Mean pain score was 2.5 per patient for the six main joints; 7.7 for the clinical score and 18.8 for the radiological score, with a mean number of bleeds of 16.3 per year per patient. During the year prior to inclusion, and because of their orthopaedic status, 22.4% of patients were hospitalized, 76.7% attended for an outpatient visit and 76.7% required at least one special investigation; 97.4% received replacement therapy, 41.4% required treatment for joint pain and 42.2% orthopaedic equipment. The less affected dimensions were the physical function (76.8 +/- 22. 2) and the social relations (76.1 +/- 23.1). Least good quality of life scores concerned the pain (60.2 +/- 25.2), perception of general health (59.3 +/- 23.1) and vitality (57.8 +/- 19.5) dimensions. The age was a discriminant criterion since quality of life was better in patients of the 18-23 age group for five dimensions. Mean annual treatment costs of a patient with severe haemophilia were determined as 425 762 French francs ($73 029). Loss of production was estimated at a mean of 4609 French francs ($791) per active patient over the course of the year. Results showed indirect evidence of the usefulness of early home treatment.

Entities:  

Mesh:

Year:  2000        PMID: 10632738     DOI: 10.1046/j.1365-2516.2000.00358.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  22 in total

1.  A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Authors:  Kathelijn Fischer; Maurice E Pouw; Daniel Lewandowski; Mart P Janssen; H Marijke van den Berg; Ben A van Hout
Journal:  Haematologica       Date:  2011-01-27       Impact factor: 9.941

2.  Activation state of platelets in experimental severe hemophilia A.

Authors:  Maud Teyssandier; Sandrine Delignat; Julie Rayes; Marijke Bryckaert; Martine Jandrot-Perrus; Srini V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

3.  Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A.

Authors:  Lusine Abrahamyan; Andrew R Willan; Joseph Beyene; Marjorie Mclimont; Victor Blanchette; Brian M Feldman
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

Review 4.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

5.  Up-regulation of platelet activation in hemophilia A.

Authors:  Esther R van Bladel; Mark Roest; Philip G de Groot; Roger E G Schutgens
Journal:  Haematologica       Date:  2011-03-21       Impact factor: 9.941

6.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

7.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

8.  Assessing quality of life in individuals with hereditary blood coagulation disorders.

Authors:  S Solovieva; N Santavirta; S Santavirta; Y T Konttinen
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

9.  Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.

Authors:  Virginie Nerich; Edgar Tissot; Albert Faradji; Karine Demesmay; Marie Anne Bertrand; Jean-Louis Lorenzini; Marie-Elisabeth Briquel; Patricia Pouzol; Marie-Christine Woronoff-Lemsi
Journal:  Pharm World Sci       Date:  2007-12-18

10.  Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A.

Authors:  Steven Pipe
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.